Join MitoAction and Dr. Jan Smeitink, CEO of Khondrion for our our March Expert Series presentation. MELAS spectrum (m.3243A>G) disorders belong to the most frequently encountered group of primary mitochondrial diseases with an unmet medical need for treatment development. Following an introduction of the clinical disease spectrum Dr. Smeitink will discuss the development and state-of-art of Khondrion’s lead product sonlicromanol.
The MitoAction committee chairs met by conference call to discuss the exciting ideas and projects ahead for 2008.
It's time to take charge of the many hours that we as patients and families spend in clinics, waiting rooms, hospitals, and healthcare provider...
What is "the Mito Cocktail"? Referring to the combination of vitamins and supplements used as therapies in the treatment and management of mitochondrial disease...